{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:03:54Z","timestamp":1780297434662,"version":"3.54.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trim.2026.102382","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:59:42Z","timestamp":1773907182000},"page":"102382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["T-cell receptor-engineered T cells (TCR-e T cells): A novel cellular therapy for hematopoietic malignancies?"],"prefix":"10.1016","volume":"96","author":[{"given":"Kajetan","family":"Karaszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wies\u0142aw Wiktor","family":"J\u0119drzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0005","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7150\/thno.104594","article-title":"Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies","volume":"15","author":"Lin","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.trim.2026.102382_bb0010","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.3389\/fimmu.2020.01689","article-title":"TCR redirected T cells for cancer treatment: achievements, hurdles, and goals","volume":"11","author":"Manfredi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2026.102382_bb0015","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.trim.2026.102382_bb0020","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3390\/cells10092379","article-title":"Evolution of CD8+ T cell receptor (TCR) engineered therapies for the treatment of cancer","volume":"10","author":"Sun","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/j.1460-2075.1993.tb05664.x","article-title":"Clonal deletion of specific thymocytes by an immunoglobulin idiotype","volume":"12","author":"Bogen","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.trim.2026.102382_bb0030","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res."},{"key":"10.1016\/j.trim.2026.102382_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR-T cells - new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.trim.2026.102382_bb0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/0113892010257212231001082741","article-title":"FDA-approved CAR T-cell therapy: a decade of progress and challenges","volume":"25","author":"Ong","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"11","key":"10.1016\/j.trim.2026.102382_bb0045","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clml.2024.06.011","article-title":"Improving access to T-cell therapies in multiple myeloma","volume":"24","author":"Derman","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \u201coff-the-shelf\u201d CAR T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"9","key":"10.1016\/j.trim.2026.102382_bb0055","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00134-024-07576-4","article-title":"Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities","volume":"50","author":"Schroeder","year":"2024","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.trim.2026.102382_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.trim.2026.102382_bb0065","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.trim.2026.102382_bb0080","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.trim.2026.102382_bb0085","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.4049\/jimmunol.146.5.1692","article-title":"MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele","volume":"146","author":"Crowley","year":"1991","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.trim.2026.102382_bb0090","first-page":"663","article-title":"The recent advancement of TCR-T cell therapies for cancer treatment","volume":"56","author":"Zhao","year":"2024","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"key":"10.1016\/j.trim.2026.102382_bb0095","article-title":"Emerging strategies in TCR-engineered T cells","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.trim.2026.102382_bb0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","article-title":"TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges","volume":"22","author":"Golikova","year":"2024","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.trim.2026.102382_bb0110","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3390\/cells9071720","article-title":"The quest for the best: how TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses","volume":"9","author":"Campillo-Davo","year":"2020","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.trim.2026.102382_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314563","article-title":"Joining forces for cancer treatment: from \u201cTCR versus CAR\u201d to \u201cTCR and CAR\u201d","volume":"23","author":"Teppert","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.trim.2026.102382_bb0125","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: state of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trim.2026.102382_bb0130","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819831068","article-title":"The emerging world of TCR-T cell trials against cancer: a systematic review","volume":"18","author":"Zhang","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"issue":"18","key":"10.1016\/j.trim.2026.102382_bb0135","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.3390\/cancers13184519","article-title":"Trial watch: adoptive TCR-engineered T-cell immunotherapy for acute myeloid leukemia","volume":"13","author":"Campillo-Davo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.trim.2026.102382_bb0140","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood.V89.4.1405","article-title":"Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia","volume":"89","author":"Inoue","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.trim.2026.102382_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.787108","article-title":"Antigen-specific TCR-T cells for acute myeloid leukemia: state of the art and challenges","volume":"12","author":"Kang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.trim.2026.102382_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-018-0720-y","article-title":"T cell receptor-engineered T cells for leukemia immunotherapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"22","key":"10.1016\/j.trim.2026.102382_bb0155","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V128.22.1001.1001","article-title":"EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML","volume":"128","author":"Chapuis","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.trim.2026.102382_bb0160","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.trim.2026.102382_bb0165","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2019-128044","article-title":"A phase I study evaluating the safety and persistence of allorestricted WT1-TCR gene modified autologous T cells in patients with high-risk myeloid malignancies unsuitable for allogeneic stem cell transplantation","volume":"134","author":"Morris","year":"2019","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.trim.2026.102382_bb0170","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3324\/haematol.2009.006486","article-title":"Development of a Wilms\u2019 tumor antigen-specific T-cell receptor for clinical trials: engineered patient\u2019s T cells can eliminate autologous leukemia blasts in NOD\/SCID mice","volume":"95","author":"Xue","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.trim.2026.102382_bb0180","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/leu.2015.155","article-title":"Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer","volume":"29","author":"Fujiwara","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.trim.2026.102382_bb0185","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.trim.2026.102382_bb0190","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers17182968","article-title":"First-in-human study of MDG1011, a TCR-T therapy directed against HLA-A*02:01-restricted PRAME antigen for high-risk myeloid and lymphoid neoplasms","volume":"17","author":"Thomas","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.trim.2026.102382_bb0195","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1158\/1078-0432.CCR-11-1066","article-title":"PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer","volume":"17","author":"Amir","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.trim.2026.102382_bb0200","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1073\/pnas.0530192100","article-title":"Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia","volume":"100","author":"Marijt","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood-2017-07-791608","article-title":"Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse","volume":"131","author":"Dossa","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.trim.2026.102382_bb0210","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.3389\/fimmu.2020.01804","article-title":"HA-1H T-cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study","volume":"11","author":"van Balen","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2010.025916","article-title":"Optimization of the HA-1-specific T-cell receptor for gene therapy of hematologic malignancies","volume":"96","author":"van Loenen","year":"2011","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.trim.2026.102382_bb0220","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2024014105","article-title":"Current developments in T-cell receptor therapy for acute myeloid leukemia","volume":"9","author":"Gore","year":"2025","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.trim.2026.102382_bb0225","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ni1001-962","article-title":"Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer","volume":"2","author":"Stanislawski","year":"2001","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1385\/IR:34:1:67","article-title":"Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression","volume":"34","author":"Voss","year":"2006","journal-title":"Immunol. Res."},{"issue":"50","key":"10.1016\/j.trim.2026.102382_bb0235","doi-asserted-by":"crossref","first-page":"86987","DOI":"10.18632\/oncotarget.18115","article-title":"Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy","volume":"8","author":"Sandri","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","article-title":"Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells","volume":"7","author":"Johanna","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"25","key":"10.1016\/j.trim.2026.102382_bb0245","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2017-02-769463","article-title":"c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals","volume":"130","author":"Nishimura","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.trim.2026.102382_bb0250","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2011-06-357939","article-title":"TCR-transgenic lymphocytes specific for HMMR\/Rhamm limit tumor outgrowth in vivo","volume":"119","author":"Spranger","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.trim.2026.102382_bb0255","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/leu.2014.131","article-title":"Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells","volume":"28","author":"Klar","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.trim.2026.102382_bb0260","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2011-06-360354","article-title":"Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity","volume":"119","author":"Nagai","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0265","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2008-06-164889","article-title":"Aurora-A kinase: a novel target of cellular immunotherapy for leukemia","volume":"113","author":"Ochi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1172\/JCI75876","article-title":"Survivin-specific T cell receptor targets tumor but not T cells","volume":"125","author":"Arber","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.trim.2026.102382_bb0275","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1172\/JCI137723","article-title":"CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia","volume":"130","author":"Biernacki","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.trim.2026.102382_bb0280","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"42","key":"10.1016\/j.trim.2026.102382_bb0285","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1038\/s41388-022-02455-y","article-title":"Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype","volume":"41","author":"Kang","year":"2022","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.trim.2026.102382_bb0290","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3324\/haematol.2019.222612","article-title":"TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment","volume":"105","author":"Depreter","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.trim.2026.102382_bb0295","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.trim.2026.102382_bb0300","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood.V122.21.4205.4205","article-title":"Preclinical evaluation of engineered T cells in multiple myeloma: uncovering a mechanism of immune escape","volume":"122","author":"Klippel","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.trim.2026.102382_bb0305","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.trim.2026.102382_bb0310","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.trim.2026.102382_bb0315","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood-2016-08-732636","article-title":"NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease","volume":"130","author":"Mastaglio","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.trim.2026.102382_bb0320","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2016-09-737536","article-title":"TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1","volume":"129","author":"Jahn","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.trim.2026.102382_bb0325","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/bloodadvances.2023010410","article-title":"Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma","volume":"7","author":"Wachsmann","year":"2023","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003715","article-title":"T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion","volume":"10","author":"Morton","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0335","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/cells11030410","article-title":"Adoptive cellular therapy for multiple myeloma using CAR- and TCR-transgenic T cells: response and resistance","volume":"11","author":"F\u00fcchsl","year":"2022","journal-title":"Cells"},{"issue":"44","key":"10.1016\/j.trim.2026.102382_bb0340","doi-asserted-by":"crossref","first-page":"71536","DOI":"10.18632\/oncotarget.12247","article-title":"A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer","volume":"7","author":"Jahn","year":"2016","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.trim.2026.102382_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq4297","article-title":"CD22 TCR-engineered T cells exert antileukemia cytotoxicity without causing inflammatory responses","volume":"11","author":"Nguyen","year":"2025","journal-title":"Sci. Adv."},{"issue":"47","key":"10.1016\/j.trim.2026.102382_bb0350","doi-asserted-by":"crossref","first-page":"77021","DOI":"10.18632\/oncotarget.12778","article-title":"Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies","volume":"7","author":"Jahn","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.trim.2026.102382_bb0355","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-15-2318","article-title":"Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies","volume":"76","author":"Sandri","year":"2016","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.trim.2026.102382_bb0360","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2012-11-465971","article-title":"Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia","volume":"121","author":"Miyazaki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trim.2026.102382_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trim.2026.102382_bb0370","article-title":"Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.trim.2026.102382_bb0375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000378","article-title":"T-cell receptor-based immunotherapy for hematologic malignancies","volume":"25","author":"Biernacki","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.trim.2026.102382_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.794183","article-title":"TCR-T immunotherapy: the challenges and solutions","volume":"11","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.trim.2026.102382_bb0385","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.trim.2026.102382_bb0390","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221142945","article-title":"Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma","volume":"30","author":"Kapinos","year":"2023","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.trim.2026.102382_bb0395","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1242\/dmm.018036","article-title":"Genetically modified T cells in cancer therapy: opportunities and challenges","volume":"8","author":"Sharpe","year":"2015","journal-title":"Dis. Model. Mech."},{"issue":"1","key":"10.1016\/j.trim.2026.102382_bb0400","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12772","article-title":"T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance","volume":"290","author":"Chandran","year":"2019","journal-title":"Immunol. Rev."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:50:18Z","timestamp":1780296618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":80,"alternative-id":["S0966327426000407"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102382","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell receptor-engineered T cells (TCR-e T cells): A novel cellular therapy for hematopoietic malignancies?","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102382"}}